查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
MicroRNAs (miRNAs) 的全球市场-2022-2029
市场调查报告书
商品编码
1129281

MicroRNAs (miRNAs) 的全球市场-2022-2029

Global MicroRNA Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

新兴国家的 COVID-19 mRNA 疫苗开发预计将推动市场增长。

由 SARS-CoV-2 引起的新型冠状病毒病 (COVID-19) 已导致全球 399,600,607 例病例和 5,757,562 人死亡。 COVID-19 对世界各地的人们构成严重的健康风险。世界卫生组织 (WHO) 已宣布 COVID-19 大流行为全球突发公共卫生事件。接种疫苗是预防流行病传播、挽救生命和保护人民健康的最成功和最具成本效益的方法。已经使用多种方法开发了 COVID-19 疫苗。其中，COVID-19信使RNA（mRNA）疫苗具有适用性广、开发週期短、易于产业化、製造工艺简单、对新亚种反应能力强、诱导免疫反应更强等优点。能力，关注度越来越高。

此外，研究人员长期以来一直在探索使用 mRNA 疫苗治疗癌症。近十年来，基于 mRNA 的癌症治疗疫苗已经在适度的研究中进行了调查，并产生了一些有希望的早期发现。例如，辉瑞生物技术公司和 Moderna 公司利用他们在生产 mRNA 癌症疫苗方面的经验来製造冠状病毒疫苗。一些研究人员希望 COVID-19 mRNA 疫苗的功效将有助于推进癌症治疗 mRNA 疫苗的临床研究。因此，从上述陈述来看，预计市场将在预测期内受到驱动。

限制

由于 microRNA (miRNA) 试剂盒成本高、耗时长，因此对 miRNA 靶点的准确计算预测是当务之急，在预测期间将解决 miRNA 的安全性和毒性问题。阻碍市场。

行业分析

MicroRNA (miRNA) Market 提供基于供应链分析、价格分析等各种行业因素的市场深度分析。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。 MicroRNAs (miRNAs) 在与病毒基因组的 3'-UTR 结合后抑制病毒翻译，或与 SARS-CoV-2 受体、结构或非结构蛋白结合，而不影响人类基因表达。您可以靶向。例如，ID02510.3p-miRNA、ID00448.3pmiRNA、miRNA 3154、miRNA 7114-5p、miRNA 5197-3p、ID02750.3p-miRNA、ID01851.5p-miRNA与SARS-CoV-2基因组和转录后结合通过抑製表达来抑制 COVID-19 的发作Nersisyan 等人将 miR-21-3p、miR-195-5p、miR-16-5p、miR-3065-5p、miR-424-5p 和 miR-424-5p 鑑定为可以直接与病毒结合的 miRNA基因组和调节所有人类冠状病毒。鑑定出六种5p，miR-421。与人类冠状病毒基因组结合最好的是 miR-21-3p。因此，COVID-19 的日益流行增加了对有效疗法的需求，推动了对下一代测序技术和 miRNA 测序仪的需求。

另一方面，大流行会破坏供应炼和流程。许多公司将转移到其他地区以确保产品可用性并保护其供应链。因此，从上述陈述来看，预计市场将受到影响，并随着经济活动的恢復而迅速获得牵引力。

此报告将提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 新兴国家的 COVID-19 mRNA 疫苗开发预计将成为市场增长的驱动力。
    • 限制因素
      • 与 microRNA (miRNA) 试剂盒相关的高成本预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品分类

  • 设备/套件
  • 消耗品
  • 试剂
  • 其他

第 8 章技术

  • 实时聚合□炼式反应
  • 微阵列
  • 二代测序 (NGS)
  • 免疫测定
  • 其他

第 9 章。按应用程序

  • 癌症
  • 感染
  • 免疫性疾病
  • 心血管疾病
  • 神经系统疾病
  • 其他

第 10 章，最终用户

  • 学术和研究机构
  • 生物製药公司
  • 委託研究机构
  • 诊断中心
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 13 章公司简介

  • Qiagen N.V.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Illumina, Inc.
  • Takara Bio, Inc
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories Inc.
  • Abcam Plc
  • GeneCopoeia, Inc.
  • System Biosciences LLC
  • Miltenyi Biotec

第14章 世界miRNA市场-DataM

简介目录
Product Code: DMBT5827

Market Overview

MicroRNA Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 19.3 % during the forecast period (2022-2029).

MicroRNAs (or miRNAs) are a new class of tiny, non-coding endogenous RNAs that control gene expression by targeting mRNAs for destruction or translational suppression. Their discovery expanded the understanding of complicated gene regulation networks in humans and animals. miRNAs influence many areas of development and physiology. Understanding its biological role is thus becoming increasingly crucial. miRNA expression analysis may provide useful information because deregulation of its function can lead to human disorders such as cancer, cardiovascular and metabolic diseases, liver problems, and immunological dysfunction.

Market Dynamics

Advances in the COVID-19 mRNA vaccine development are expected to drive market growth.

The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has resulted in 399,600,607 cases and 5,757,562 deaths globally. COVID-19 is a severe hazard to human health around the world. The COVID-19 pandemic has been labeled a global public health emergency by the World Health Organization (WHO). Vaccination is the most successful and cost-efficient method for preventing the spread of the epidemic, saving lives and protecting population health. COVID-19 vaccines have been developed using a variety of ways. Among these, the COVID-19 messenger RNA (mRNA) vaccine has received increased attention due to its broad application potential and benefits, which include a short development cycle, ease of industrialization, a simple manufacturing process, the ability to respond to new variants, and the ability to induce a stronger immune response.

Moreover, researchers have long sought to use mRNA vaccines for cancer treatment. For nearly a decade, mRNA-based cancer therapy vaccines have been studied in modest studies, with some encouraging early findings. For instance, Pfizer-BioNTech and Moderna used their experience generating mRNA cancer vaccines to build coronavirus vaccines. Some researchers anticipate that the effectiveness of the mRNA COVID-19 vaccines may help advance clinical research on mRNA vaccines for cancer treatment. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

High costs associated with the miRNA kits are time-consuming, making the accurate computational prediction of miRNA targets a high priority; safety and toxicity issues of miRNA are some of the factors the market is expected to get hampered in the forecast period.

Industry Analysis

The microRNA market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. miRNAs can inhibit the viral translation after the attachment of miRNAs to 3'-UTR of the viral genome or target the receptors, structural or nonstructural proteins of SARS-CoV-2 without affecting the expression of human genes. For instance, ID02510.3p-miRNA, ID00448.3pmiRNA, miRNA 3154, miRNA 7114-5p, miRNA 5197-3p, ID02750.3p-miRNA, and ID01851.5p-miRNA attenuate COVID-19 disease development by binding to the SARS-CoV-2 genome and inhibiting its post-transcriptional expression. Nersisyan et al. identified six miRNAs, including miR-21-3p, miR-195-5p, miR-16-5p, miR-3065-5p, miR-424-5p, and miR-421, that could regulate all human coronaviruses by binding directly to the viral genome. The best binding to the human coronavirus genome was found at miR-21-3p. Therefore, because of the increased COVID-19 infection, there is a greater need for effective therapy, which raises the demand for next-generation sequencing technologies and miRNA sequencing.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Real Time Polymerase Chain Reaction segment is expected to hold the largest market share in microRNA market

The real-time polymerase chain reaction segment is expected to dominate in 2021. The segment benefits because it has a wide dynamic range, excellent sensitivity, can be very sequence-specific, requires little to no post-amplification processing, and can be scaled up to increase sample throughput. Moreover, the research of gene expression has been transformed by RT-PCR. The RNA transcript of any gene can now theoretically be detected, regardless of the scarcity of the starting material or the relative abundance of the specific mRNA. RT-PCR involves using a retroviral reverse transcriptase to copy an RNA template into complementary DNA (cDNA). PCR is then used to amplify the cDNA exponentially. RT-PCR, like NPAs, is fairly tolerant of degraded RNA. The target will be amplified if the RNA is intact inside the region spanned by the primers.

Moreover, Tata MD launched COVID express RT-PCR testing solutions in December 2021. Tata MD CHECK XF, a 3-Gene RT-PCR kit that does not require RNA extraction and uses a fast amplification procedure, is combined with a portable and quick qPCR analyzer and Tata MD CHECK RT-PCR Fast 3 Gene. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global microRNA market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of cancer and infectious diseases, rising demand for next-generation and microRNA services and applications in drug development, adoption of the latest technology, and established research infrastructure for proteomics, genomics, and oncology, rising patent approvals for their miRNA biomarkers and product launches by the key market players are some of the factors the market is expected to boost in the forecast period. For instance, in the United States, in 2019, 1,752,735 new cancer cases were reported, and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported, and 146 people died of cancer. In contrast, In the United States, however, 2 million new cancer cases were identified in 2020, with 612,390 deaths. This shows that the cancer incidence and mortality rate are very high, increasing the demand for precision medications and therapies for patients and raising the demand for microRNA approaches in the region.

Moreover, On Oct. 21, 2021, Interpace Biosciences, Inc. announced that the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for the use of microRNAs in the differentiation of benign from malignant thyroid neoplasms. This patent covers the technology that underpins its ThyraMIR microRNA Classifier. MicroRNAs are short non-coding RNAs that bind to messenger RNA and influence protein expression in human malignancies, including thyroid cancer. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the microRNA market are Qiagen N.V., Illumina, Inc., Takara Bio, Inc, PerkinElmer, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Abcam Plc, GeneCopoeia, Inc., System Biosciences LLC, Miltenyi Biotec.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and based in Waltham, Massachusetts. The company offers worldwide life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Product Portfolio:

TaqMan miRNA Assays: TaqMan MicroRNA Assays from Applied Biosystems quantify miRNAs using the specificity and sensitivity of TaqMan Assay chemistry. A straightforward two-step approach consists of reverse transcription using a miRNA-specific primer, followed by real-time PCR using TaqMan probes. TaqMan MicroRNA Assays are highly specific, sensitive, quick, easy to use, and scalable.

The global microRNA market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advances in the COVID-19 mRNA vaccine development are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High costs associated with the miRNA kits are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Instruments & Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Consumables
  • 7.4. Reagents
  • 7.5. Others

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Real Time Polymerase Chain Reaction*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Microarray
  • 8.4. Next Generation Sequencing (NGS)
  • 8.5. Immunoassay
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Infectious Diseases
  • 9.4. Immunological Disorder
  • 9.5. Cardiovascular Disease
  • 9.6. Neurological Disease
  • 9.7. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Academic and Research Institutes*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Biopharmaceutical Companies
  • 10.4. Contract Research Organizations
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Qiagen N.V.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Illumina, Inc.
  • 13.3. Takara Bio, Inc
  • 13.4. PerkinElmer, Inc.
  • 13.5. Thermo Fisher Scientific
  • 13.6. Bio-Rad Laboratories Inc.
  • 13.7. Abcam Plc
  • 13.8. GeneCopoeia, Inc.
  • 13.9. System Biosciences LLC
  • 13.10. Miltenyi Biotec

LIST NOT EXHAUSTIVE

14. Global MicroRNA Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us